She will also continue to serve as president of the Astellas U.S.A. Foundation.
Former Edelman executive Mary Corcoran replaces Annalise Coady, who becomes president of W2O EMEA.
Celgene and Agios secure FDA approval for AML drug Idhifa; GSK hires chief digital and technology officer; Pfizer wants tax reform before M&A engagement
FDA launches digital health pre-certification pilot; J&J's experimental RA drug raises safety concerns; AstraZeneca gets breakthrough status for Imfinzi
Generic drugmakers reportedly seeking deals; GSK to refocus R&D; Merck and AstraZeneca to test combo cancer drug
David Musselman and Lynn Gerber are now leading sales for the company's primary care and specialty products.
Biogen reports better-than-expected Spinraza sales; FDA to discuss opioid prescriptions with payers; UnitedHealth Group launches media review
Novartis raises Alcon forecast; UDG acquires Cambridge BioMarketing; Spark Therapeutics receives priority review for Luxturna gene therapy
AstraZeneca CEO reportedly moving to Teva; the FDA reverses on approval for Amicus drug; Merck names winners of Alexa challenge
The CEOs of the industry's largest holding companies discuss how they're reasserting their businesses.
Discover how M&A activity in 2016 and 2017 has reshaped North American healthcare agencies and the holding companies that own them.
Walgreens ends merger with Rite Aid; Biogen hires former Novartis exec as SVP of corporate affairs; FDA takes new measures to drive drug pricing competition
Alison Lewis, the global chief marketing officer of Johnson & Johnson consumer division, has little appetite for new flavours and variants but instead wants to rethink innovation as a means to solve consumer problems.
The video is part of Pfizer's ongoing corporate ad campaign Before it Became a Medicine.
Adamis receives FDA approval for EpiPen rival Symjepi; Clovis reports positive trial results for ovarian cancer drug Rubraca; hedge fund billionaire John Paulson joins Valeant board of directors
The tone has changed dramatically since last year for LGBT rights groups, which are now as focused on opposing the Trump administration's policies as celebrating progress and community.
Drug prices, as you may have heard, are kind of high. But price growth has slowed after sharp spikes in 2014 and 2015.
Hepatitis C is so 2015 — at least, that's what Gilead Sciences CEO John Milligan is saying following his first year at the helm.
Is Pfizer finally in a position to close the Lipitor chapter, the one titled "how to bounce back from monumental loss"? All signs indicate yes.
After mulling over M&A options, Johnson & Johnson sprang into action in pursuit of Swiss biotech Actelion and initially received muted applause from investors.
The Kenilworth, New Jersey, company expects 2017 to produce the same worldwide sales scenario as last year. Yet despite the cautious outlook, stock prices are hovering higher than they were at this time in 2016.
Biotech major Amgen is making good on a lofty promise to generate $1.5 billion in savings by 2018.
The 2016 headliner for Teva Pharmaceutical Industries was its acquisition of Actavis Generics, which sent $33.43 billion in cash and about 100 million Teva shares to Allergan.
Any conversation about AbbVie has to begin with Humira, the best-selling drug in the world and the drugmaker's most important product.
Sanofi has been browsing in the acquisition aisle for some time now, even wheeling a few companies to the register only to leave empty-handed.
The FDA made patients, providers, and investors very happy when it approved Roche's Ocrevus in March.
Following one of the most anticipated exclusivity losses of the decade, sales of Novartis cancer drug Gleevec slipped 28% in 2016 to $3.3 billion.
Eli Lilly has faced a rough patch. Last November, the company took a $150 million charge over its failed high-profile Alzheimer's disease drug solanezumab.
AstraZeneca brought its internal overhaul A game in 2016, leaving investors humming the tune of a much-needed turning point.
FDA presents ideas to tackle drug prices; patients aware of side effects more likely to report them; scientists use Apple's Research Kit for clinical purposes